Literature DB >> 1878732

The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomized controlled trial.

G Visani1, B Gamberi, P Greenberg, R Advani, S Gulati, R Champlin, M Hoglund, C Karanes, S Williams, A Keating.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1878732

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

1.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial.

Authors:  B R Luce; J W Singer; J M Weschler; C D Buckner; S H Sheingold; K Shannon-Dorcy; F R Appelbaum; J Nemunaitis
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

Review 3.  The side-effect profile of GM-CSF.

Authors:  A C Stern; T C Jones
Journal:  Infection       Date:  1992       Impact factor: 3.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.